MoA studies of molecules derived from TB bacteria for the treatment of asthma

农业部对源自结核菌的分子用于治疗哮喘的研究

• 批准号: 132034
• 金额: $ 17.84万
• 依托单位: PEPTINNOVATE LIMITED
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=132034
• 关键词: MoA; studies; molecules; derived; TB

Peptinnovate have discovered that proteins derived from mycobacterium tuberculosis (mTB) unexpectedly act as potent anti-inflammatory agents both in vivo (animal) and in vitro (human and animal), via an unknown mechanism of action. Peptide fragments of the mTB protein have been successfully synthesised and shown to have equivalent or augmented activity in these systems. This project focuses on the use of these proprietary compounds to probe their mechanism of action for use in steroid resistant asthma supporting Peptinnovate's (SME) growth strategy. We will use innovative in vitro and in vivo techniques on human immune cells and in animal models. The resulting mechanistic understanding will allow Peptinnovate to be potentially the first to develop new medicines based on the unique properties of mTB proteins, making Peptinnovate an attractive licence partner, increasing UK investment, and providing therapeutic options to the patients.

Peptinnovate发现，结核分枝杆菌（mTB）衍生的蛋白质通过未知的作用机制在体内（动物）和体外（人类和动物）均意外地发挥强效抗炎剂的作用。已经成功合成了mTB蛋白的肽片段，并显示在这些系统中具有等同或增强的活性。该项目的重点是使用这些专利化合物来探索其用于类固醇抵抗性哮喘的作用机制，以支持Peptinnovate（SME）的增长战略。我们将在人体免疫细胞和动物模型中使用创新的体外和体内技术。由此产生的机制理解将使Peptinnovate成为第一个基于mTB蛋白质独特特性开发新药的潜在公司，使Peptinnovate成为有吸引力的许可合作伙伴，增加英国投资，并为患者提供治疗选择。